Legal Guide
Understanding Psychedelic Legalization
The legal landscape for psychedelic therapy is changing fast — but unevenly. Three states have passed laws, dozens of cities have decriminalized, and legislation is moving across the country. Here's what's actually happening, what it means, and where things are headed.
Last updated April 2026
Fully Operational
These states have legal, regulated psychedelic therapy programs with licensed providers actively serving clients.
Psilocybin Services Act (Measure 109) — Effective January 2023
Oregon became the first state to legalize regulated psilocybin therapy. Licensed facilitators guide clients through sessions at approved service centers. No prescription or diagnosis required — any adult 21+ can access services. Over 10,000 clients served since launch, though a third of service centers have closed due to high operating costs.
You can book a legal psilocybin session in Oregon today. Sessions cost $1,000–$3,500 and include preparation, administration, and integration support.
Natural Medicine Health Act — Passed November 2022, Centers Open 2025
Colorado's Proposition 122 legalized regulated access to psilocybin and psilocin, with DMT, ibogaine, and mescaline (non-peyote) under review for addition in 2026. 34 state-licensed healing centers have been approved, with multiple operating in Boulder and other cities. 10 facilitator training programs approved.
You can book a legal psilocybin session at licensed healing centers in Colorado today. Facilitator training programs are enrolling — a major opportunity for practitioners.
Legal, Launching
These states have passed legalization laws, but programs are still being built or haven't started yet.
Medical Psilocybin Act — Signed April 2025
New Mexico became the third state to legalize psilocybin access and the first to do so through legislation (Oregon and Colorado used ballot measures). Unlike those states, New Mexico uses a medical model — patients need qualifying conditions (treatment-resistant depression, PTSD, substance use disorders, end-of-life care) and a physician referral. Passed with strong bipartisan support (House 56-8, Senate 33-4).
No services yet. The DOH is drafting rules and aims to have initial patients seen by late 2026 — a year ahead of the December 2027 full implementation deadline.
Psilocybin Therapy — Signed June 2025, Conditional on FDA Approval
Arizona signed SB 1555 allowing pharmaceutical psilocybin to be prescribed if approved by the FDA and rescheduled by the DEA (by January 2031). The state must begin licensing psychedelic-assisted therapy centers by January 2027. Arizona also earmarked $5M for psilocybin research and approved a first-in-the-nation whole mushroom psilocybin clinical trial for veterans and first responders.
No therapy access yet. This law only activates when the FDA approves psilocybin — but Arizona will be ready to move quickly when that happens.
Decriminalized
These cities and jurisdictions have reduced or eliminated penalties for possession of psychedelic substances.
Decriminalized does not mean legal therapy is available. These jurisdictions have reduced penalties for personal possession, but there are no regulated therapy programs or licensed providers. You cannot legally access guided psychedelic therapy in these areas.
Active Legislation
Bills and ballot measures currently working their way through state legislatures.
HF 978
Would establish a Psilocybin Production Establishment Licensing Board. Advancing in Senate.
HB 717
Would require ketamine therapy clinics to be physician-owned and licensed by the Georgia Medical Board by July 2027.
HF 2906
Psilocybin therapeutic use program. Would license 20-50 facilitators and reclassify psilocybin to Schedule IV. Bipartisan support.
SB 5921
Psilocybin access bill. Companion bill HB 1433 also introduced.
Alaska Natural Medicine Act
Failed to collect enough signatures for 2026. Campaign pivoting to 2028 cycle. Would decriminalize and regulate psilocybin, DMT, and mescaline.
Research Only
These states are investing in psychedelic research but have no patient access programs.
Ibogaine Research Program — Signed June 2025
Texas signed SB 2308 allocating up to $100 million for ibogaine research at state universities, focused on treating PTSD and traumatic brain injury in veterans. Unable to find a drug company partner, Texas is launching its own clinical trials in partnership with medical researchers. This is a research-only program — there is no legal patient access to ibogaine therapy in Texas.
No therapy access. This is purely research funding. If clinical trials succeed, it could pave the way for future legalization efforts, particularly for veteran care.
Visual Overview
See the full picture at a glance — click any state to learn more
Psychedelic Access in Canada
Canada takes a different approach than the US — federal programs rather than state-by-state legalization.
Special Access Program (SAP)
ActiveSince January 2022, physicians can request psilocybin and MDMA through Health Canada's Special Access Program for patients with serious or life-threatening conditions. This is not a general therapy program — each request is reviewed individually.
Ketamine Clinics
Widely AvailableKetamine is a legal prescription medication in Canada. Dozens of clinics across major cities offer ketamine-assisted therapy for treatment-resistant depression, PTSD, and chronic pain.
BC Decriminalization Pilot
Ended Jan 2025British Columbia ran a pilot decriminalizing possession of small amounts of opioids, cocaine, meth, and MDMA (not psilocybin). After public spaces were re-criminalized in Sept 2023, the federal exemption was not renewed and the pilot ended in January 2025.
What Does This Mean For You?
Whether you're exploring therapy, building a career, or tracking the industry
I want to try psychedelic therapy
Browse licensed facilitators and service centers in states where therapy is legal today.
Browse providers →I work in this field
Find job openings at psychedelic companies, research institutions, and therapy centers.
View jobs →I want to learn more
Explore substances, clinical trials, and the science behind psychedelic medicine.
Explore substances →Explore by Substance
Legal status, clinical trials, and research for each psychedelic